Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV Type 1-infected subjects over 48 weeks

AIDS Research and Human Retroviruses

Volumn 28, Issue 10, 2012, Pages 1184-1195

  Aberg, Judith A ^a   Tebas, Pablo ^b   Overton, Edgar Turner ^c   Gupta, Samir K ^d   Sax, Paul E ^e   Landay, Alan ^f   Falcon, Ron ^g   Ryan, Robert ^g   De La Rosa, Guy ^g  

^a BELLEVUE HOSPITAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD28 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; CHOLESTEROL; CREATININE; D DIMER; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HLA DR ANTIGEN; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; KI 67 ANTIGEN; LIPID; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR RECEPTOR 2; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; ADIPOSE TISSUE; ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL TRANSLOCATION; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEHYDRATION; DERMATITIS; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXPLORATORY RESEARCH; EYE JAUNDICE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; INFLAMMATION; INSULIN SENSITIVITY; JOINT SWELLING; LABORATORY TEST; LEUKOCYTOCLASTIC VASCULITIS; MAJOR CLINICAL STUDY; MALE; METABOLISM; MULTICENTER STUDY; NEUTROPENIA; NEUTROPHIL; PANCREATITIS; PATIENT COMPLIANCE; PERCEPTION; PHASE 4 CLINICAL TRIAL; PILOT STUDY; POLLAKISURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SODIUM BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PILOT PROJECTS; PYRIDINES; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84866640966     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0327     Document Type: Article

References (58)

1. Phillips AN, Neaton J, Lundgren JD: The role of HIV in serious diseases other than AIDS. AIDS 2008;22:2409-2418.
2. Neuhaus J, Jacobs DR, Baker JV, et al.: Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010;201:1788-1795.
3. Friis-Moller N, Reiss P, Sabin CA, et al.: Class of anti-retroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-1735.
4. Flint OP, Noor MA, Hruz PW, et al.: The role of protease inhibitors in the pathogenesis of HIV-associated lipody-strophy: Cellular mechanisms and clinical implications. Toxicol Pathol 2009;37:65-77.
5. Haubrich RH, Riddler SA, DiRienzo AG, et al.: Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009;23:1109-1118.
6. Stein JH, Komarow L, Cotter BR, et al.: Lipoprotein changes in HIV-infected antiretroviral-naive individuals after starting antiretroviral therapy: ACTG Study A5152s Stein: Li-poprotein Changes on Antiretroviral Therapy. J Clin Lipidol 2008;2:464-471.
7. Zhou H, Jarujaron S, Gurley EC, et al.: HIV protease inhibitors increase TNF-alpha and IL-6 expression in macro-phages: Involvement of the RNA-binding protein HuR. Atherosclerosis 2007;195:e134-143.
8. Carper MJ, Cade WT, Cam M, et al.: HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 2008;294:E558-567.
9. Noor MA, Lo JC, Mulligan K, et al.: Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001;15: F11-18.
10. Noor MA, Parker RA, O'Mara E, et al.: The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004;18:2137-2144.
11. Noor MA, Seneviratne T, Aweeka FT, et al.: Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study. AIDS 2002;16:F1-8.
12. Dube MP, Shen C, Greenwald M, and Mather KJ: No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopina-vir-ritonavir in healthy subjects without HIV infection: A placebo-controlled trial. Clin Infect Dis 2008;47:567-574.
13. Lee GA, Seneviratne T, Noor MA, et al.: The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004;18: 641-649.
14. Hui DY: Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 2003;42:81-92.
15. Melroe NH, Kopaczewski J, Henry K, and Huebsch J: Lipid abnormalities associated with protease inhibitors. J Assoc Nurses AIDS Care 1999;10:22-30.
16. Periard D, Telenti A, Sudre P, et al.: Atherogenic dyslipide-mia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999;100:700-705.
17. Purnell JQ, Zambon A, Knopp RH, et al.: Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000;14:51-57.
18. Riddler SA, Li X, Otvos J, et al.: Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2008;48:281-288.
19. Hammond E, McKinnon E, and Nolan D: Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: Prevalence and metabolic consequences. Clin Infect Dis 2010;51:591-599.
20. Martinez E, Mocroft A, Garcia-Viejo MA, et al.: Risk of lipo-dystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study. Lancet 2001;357: 592-598.
21. Tsiodras S, Mantzoros C, Hammer S, and Samore M: Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study. Arch Intern Med 2000;160:2050-2056.
22. Walmsley S, Cheung AM, Fantus G, et al.: A prospective study of body fat redistribution, lipid, and glucose parameters in HIV-infected patients initiating combination anti-retroviral therapy. HIV Clin Trials 2008;9:314-323.
23. Innes S, Levin L, and Cotton M: Lipodystrophy syndrome in HIV-infected children on HAART. South Afr J HIV Med 2009;10:76-80.
24. Safrin S and Grunfeld C: Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999;13:2493-2505.
25. Tsiodras S, Perelas A, Wanke C, and Mantzoros CS: The HIV-1/HAART associated metabolic syndrome-novel adi-pokines, molecular associations and therapeutic implications. J Infect 2010;61:101-113.
26. Cunningham WE, Crystal S, Bozzette S, and Hays RD: The association of health-related quality of life with survival among persons with HIV infection in the United States. J Gen Intern Med 2005;20:21-27.
27. de Boer-van der Kolk IM, Sprangers MA, Prins JM, Smit C, de Wolf F, and Nieuwkerk PT: Health-related quality of life and survival among HIV-infected patients receiving highly active antiretroviral therapy: A study of patients in the AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort. Clin Infect Dis 2010;50:255-263.
28. Rajagopalan R, Laitinen D, and Dietz B: Impact of lipoa-trophy on quality of life in HIV patients receiving anti-ret-roviral therapy. AIDS Care 2008;20:1197-1201.
29. Carter VM, Hoy JF, Bailey M, Colman PG, Nyulasi I, and Mijch AM: The prevalence of lipodystrophy in an ambulant HIV-infected population: It all depends on the definition. HIV Med 2001;2:174-180.
30. Currier JS, Martorell C, Osiyemi O, et al.: Effects of dar-unavir/ritonavir-based therapy on metabolic and anthro-pometric parameters in women and men over 48 weeks. AIDS Patient Care STDS 2011;25:333-340.
31. Kelly JS, Langdon D, and Serpell L: The phenomenology of body image in men living with HIV. AIDS Care 2009;21: 1560-1567.
32. Baraldi E, Morales-Ramírez J, Schneider S, et al.: Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on lipid parameters and anthropometrics in treatment-naive, HIV-1-infected ARTEMIS patients at Week 96. Presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, July 19-22, 2009. Poster MOPEB034.
33. Tomaka F, Lefebvre E, Sekar V, et al.: Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers. HIV Med 2009;10:318-327.
34. Molina JM, Andrade-Villanueva J, Echevarria J, et al.: Once-daily atazanavir/ritonavir compared with twice-daily lopi-navir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2008;53:323-332.
35. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Trea-cher DF, and Turner RC: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
36. Borai A, Livingstone C, and Ferns GA: The biochemical assessment of insulin resistance. Ann Clin Biochem 2007; 44:324-342.
37. Neidig JL, Holmes W, Reynolds NR, et al.: ACTG 5089: Development of assessment of body change distress (ABCD) questionnaire for evaluation of fat redistribution. Presented at the XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002. Abstract B10609.
38. Riddler SA, Smit E, Cole SR, et al.: Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289:2978-2982.
39. Mills AM, Nelson M, Jayaweera D, et al.: Once-daily dar-unavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009;23: 1679-1688.
40. Baker J, Ayenew W, Quick H, et al.: High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis 2010;201:285-292.
41. Norris PJ, Pappalardo BL, Custer B, Spotts G, Hecht FM, and Busch MP: Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses 2006;22:757-762.
42. Stacey AR, Norris PJ, Qin L, et al.: Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009;83:3719-3733.
43. Roberts L, Passmore JA, Williamson C, et al.: Plasma cyto-kine levels during acute HIV-1 infection predict HIV disease progression. AIDS 2010;24:819-831.
44. Sachdeva RK, Wanchu A, Bagga R, Malla N, and Sharma M: Effect of non-nucleoside reverse transcriptase inhibitors on cytokine, chemokine, and immunoglobulin profiles in serum and genital secretions of HIV-infected women. J Interferon Cytokine Res 2009;30:13-24.
45. Ford ES, Greenwald JH, Richterman AG, et al.: Traditional risk factors and d-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS 2010;24:1509-1517.
46. Baker JV, Neuhaus J, Duprez D, et al.: Changes in inflammatory and coagulation biomarkers: A randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 2010;56:36-43.
47. Brenchley JM, Price DA, Schacker TW, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-1371.
48. Shikuma CM, Ribaudo HS, and Zheng E: 96 week effects of suppressive efavirenz-containing antiretroviral therapy, abacavir, and sex on hs-CRP in ACTG A5095. Presented at the 16th Conference on Retroviruses and Opportunistic Infections, Montréal, Canada, February 8-11, 2009. Poster 736.
49. Kestens L, Vanham G, Gigase P, et al.: Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection. AIDS 1992;6:793-797.
50. Kestens L, Vanham G, Vereecken C, et al.: Selective increase of activation antigens HLA-DR and CD38 on CD4 + CD45RO+ T lymphocytes during HIV-1 infection. Clin Exp Immunol 1994;95:436-441.
51. Angel JB, Kumar A, Parato K, et al.: Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquina-vir. J Infect Dis 1998;177:898-904.
52. Ondoa P, Koblavi-Deme S, Borget MY, Nolan ML, Nkenga-song JN, and Kestens L: Assessment of CD8 T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1-infected patients in Cote dÍvoire. Clin Exp Immunol 2005;140:138-148.
53. Steel A, John L, Shamji MH, et al.: CD38 expression on CD8 T cells has a weak association with CD4 T-cell recovery and is a poor marker of viral replication in HIV-1-infected patients on antiretroviral therapy. HIV Med 2008;9: 118-125.
54. Busti AJ, Bedimo R, Margolis DM, and Hardin DS: Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir. J Investig Med 2008;56:539-544.
55. Noor M, Maa J, Witek J, and Falutz J: Predictive accuracy of surrogate indices for predicting early insulin resistance after treatment with HIV protease inhibitors (PI). Poster presented at the 44th Annual Meeting of the Infectious Diseases Society of America (IDSA), Toronto, Canada, October 12-15, 2006. Poster 986.
56. Mocroft A, Kirk O, Reiss P, et al.: Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010;24:1667-1678.
57. Grunfeld C, Saag M, Cofrancesco J Jr, et al.: Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy. AIDS 2010;24:1717-1726.
58. REYATAZ (atazanavir): Full prescribing Information. Accessed from http://packageinserts.bms.com/pi/pi-reyataz.pdf on August 17, 2010.